Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study
During adjuvant abemaciclib, low-moderate-grade toxicities were common, particularly haematological and gastrointestinal events. Older patients showed a numerically higher rate of dose reductions, suggesting a potential need for personalized dosing and early monitoring in this subgroup. These findings should be considered hypothesis-generating and warrant confirmation in larger prospective studies.
Authors
- Laura D. Locati (ORCID: https://orcid.org/0000-0003-3315-2580)
- Lorenzo Perrone (ORCID: https://orcid.org/0000-0001-5273-9788)
- Angioletta Lasagna (ORCID: https://orcid.org/0000-0002-9611-1164)
- Giulia Gambini (ORCID: https://orcid.org/0009-0003-0795-7972)
- Alessandra Ferrari (ORCID: https://orcid.org/0000-0001-7354-9895)
- Gavino Chessa
- Raffaella Palumbo (ORCID: https://orcid.org/0000-0002-3997-983X)
- Erica Quaquarini (ORCID: https://orcid.org/0000-0001-9099-5352)
- Simone Figini
- Paolo Pedrazzoli (ORCID: https://orcid.org/0000-0002-9419-7160)
- Barbara Tagliaferri (ORCID: https://orcid.org/0000-0002-4889-5574)
- Catherine Klersy (ORCID: https://orcid.org/0000-0003-0314-8548)
- Federico Sottotetti (ORCID: https://orcid.org/0000-0002-9679-6538)
- Gianpiero Rizzo
Institutions
- University of Pavia (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Drugs in Context
- Published
- 2025-12-09
- DOI
- https://doi.org/10.7573/dic.2025-7-5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00